162 related articles for article (PubMed ID: 35868123)
1. Current progress and novel strategies that target CDK12 for drug discovery.
Lei P; Zhang J; Liao P; Ren C; Wang J; Wang Y
Eur J Med Chem; 2022 Oct; 240():114603. PubMed ID: 35868123
[TBL] [Abstract][Full Text] [Related]
2. Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor.
Niu T; Li K; Jiang L; Zhou Z; Hong J; Chen X; Dong X; He Q; Cao J; Yang B; Zhu CL
Eur J Med Chem; 2022 Jan; 228():114012. PubMed ID: 34864331
[TBL] [Abstract][Full Text] [Related]
3. Dual Inhibition of CDK12/CDK13 Targets Both Tumor and Immune Cells in Ovarian Cancer.
Cheng L; Zhou S; Zhou S; Shi K; Cheng Y; Cai MC; Ye K; Lin L; Zhang Z; Jia C; Xiang H; Zang J; Zhang M; Yin X; Li Y; Di W; Zhuang G; Tan L
Cancer Res; 2022 Oct; 82(19):3588-3602. PubMed ID: 35857807
[TBL] [Abstract][Full Text] [Related]
4. Development, validation, and evaluation of a deep learning model to screen cyclin-dependent kinase 12 inhibitors in cancers.
Wen T; Wang J; Lu R; Tan S; Li P; Yao X; Liu H; Yi Z; Li L; Liu S; Gao P; Qian H; Xie G; Ma F
Eur J Med Chem; 2023 Mar; 250():115199. PubMed ID: 36827953
[TBL] [Abstract][Full Text] [Related]
5. The promise and current status of CDK12/13 inhibition for the treatment of cancer.
Tadesse S; Duckett DR; Monastyrskyi A
Future Med Chem; 2021 Jan; 13(2):117-141. PubMed ID: 33295810
[TBL] [Abstract][Full Text] [Related]
6. A patent and literature review of CDK12 inhibitors.
Tang R; Liu J; Li S; Zhang J; Yu C; Liu H; Chen F; Lv L; Zhang Q; Yuan K; Shao H
Expert Opin Ther Pat; 2022 Oct; 32(10):1055-1065. PubMed ID: 36120913
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 3-Benzyl-1-( trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea Derivatives as Novel and Selective Cyclin-Dependent Kinase 12 (CDK12) Inhibitors.
Ito M; Tanaka T; Toita A; Uchiyama N; Kokubo H; Morishita N; Klein MG; Zou H; Murakami M; Kondo M; Sameshima T; Araki S; Endo S; Kawamoto T; Morin GB; Aparicio SA; Nakanishi A; Maezaki H; Imaeda Y
J Med Chem; 2018 Sep; 61(17):7710-7728. PubMed ID: 30067358
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13.
Yang J; Chang Y; Tien JC; Wang Z; Zhou Y; Zhang P; Huang W; Vo J; Apel IJ; Wang C; Zeng VZ; Cheng Y; Li S; Wang GX; Chinnaiyan AM; Ding K
J Med Chem; 2022 Aug; 65(16):11066-11083. PubMed ID: 35938508
[TBL] [Abstract][Full Text] [Related]
9. Human CDK12 and CDK13, multi-tasking CTD kinases for the new millenium.
Greenleaf AL
Transcription; 2019 Apr; 10(2):91-110. PubMed ID: 30319007
[TBL] [Abstract][Full Text] [Related]
10. CDK12: an emerging therapeutic target for cancer.
Lui GYL; Grandori C; Kemp CJ
J Clin Pathol; 2018 Nov; 71(11):957-962. PubMed ID: 30104286
[TBL] [Abstract][Full Text] [Related]
11. [Function of CDK12 in Tumor initiation and progression and its clinical consequences].
Vrábel D; Svoboda M; Navrátil J; Kohoutek J
Klin Onkol; 2014; 27(5):340-6. PubMed ID: 25312711
[TBL] [Abstract][Full Text] [Related]
12. Discovery and resistance mechanism of a selective CDK12 degrader.
Jiang B; Gao Y; Che J; Lu W; Kaltheuner IH; Dries R; Kalocsay M; Berberich MJ; Jiang J; You I; Kwiatkowski N; Riching KM; Daniels DL; Sorger PK; Geyer M; Zhang T; Gray NS
Nat Chem Biol; 2021 Jun; 17(6):675-683. PubMed ID: 33753926
[TBL] [Abstract][Full Text] [Related]
13. Role and therapeutic potential of CDK12 in human cancers.
Chilà R; Guffanti F; Damia G
Cancer Treat Rev; 2016 Nov; 50():83-88. PubMed ID: 27662623
[TBL] [Abstract][Full Text] [Related]
14. Transcription-associated cyclin-dependent kinase 12 (CDK12) as a potential target for cancer therapy.
Wu W; Yu S; Yu X
Biochim Biophys Acta Rev Cancer; 2023 Jan; 1878(1):188842. PubMed ID: 36460141
[TBL] [Abstract][Full Text] [Related]
15. Research progress of anticancer drugs targeting CDK12.
Yan Z; Du Y; Zhang H; Zheng Y; Lv H; Dong N; He F
RSC Med Chem; 2023 Sep; 14(9):1629-1644. PubMed ID: 37731700
[TBL] [Abstract][Full Text] [Related]
16. Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors.
Joshi PM; Sutor SL; Huntoon CJ; Karnitz LM
J Biol Chem; 2014 Mar; 289(13):9247-53. PubMed ID: 24554720
[TBL] [Abstract][Full Text] [Related]
17. Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids.
Cesari E; Ciucci A; Pieraccioli M; Caggiano C; Nero C; Bonvissuto D; Sillano F; Buttarelli M; Piermattei A; Loverro M; Camarda F; Greco V; De Bonis M; Minucci A; Gallo D; Urbani A; Vizzielli G; Scambia G; Sette C
J Exp Clin Cancer Res; 2023 May; 42(1):126. PubMed ID: 37202753
[TBL] [Abstract][Full Text] [Related]
18. CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion.
Tien JF; Mazloomian A; Cheng SG; Hughes CS; Chow CCT; Canapi LT; Oloumi A; Trigo-Gonzalez G; Bashashati A; Xu J; Chang VC; Shah SP; Aparicio S; Morin GB
Nucleic Acids Res; 2017 Jun; 45(11):6698-6716. PubMed ID: 28334900
[TBL] [Abstract][Full Text] [Related]
19. Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12/CycK complex.
Ekumi KM; Paculova H; Lenasi T; Pospichalova V; Bösken CA; Rybarikova J; Bryja V; Geyer M; Blazek D; Barboric M
Nucleic Acids Res; 2015 Mar; 43(5):2575-89. PubMed ID: 25712099
[TBL] [Abstract][Full Text] [Related]
20. CDK12: a potential therapeutic target in cancer.
Emadi F; Teo T; Rahaman MH; Wang S
Drug Discov Today; 2020 Dec; 25(12):2257-2267. PubMed ID: 33038524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
